MetaCap

Medicus Pharma Ltd. (MDCX)

NASDAQ: MDCXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.14-0.025 (-2.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MDCX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$76.65
52-week range
1.06 – 114.00
Day range
1.06 – 1.23
Volume / Avg
86.72K / 116.55K
Beta
—

52-week range

$1.06$114.00

MDCX stock today

Medicus Pharma (MDCX) closed at $1.14 on Nov 20, down 2.16% (-$0.025), versus the S&P 500's 3.70% decline. At this level, MDCX sits near the bottom of its 52-week range of $1.06 to $114.00: 99.0% below the high and 7.1% above the low. MDCX is down 25.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.7%.

Medicus Pharma has posted a net loss over the last twelve months (EPS of -$76.65), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Medicus Pharma

Company profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Raza Bokhari M.B.A., M.D.
Headquarters
West Conshohocken, PA
Employees
16

Financial highlights

Full financials

Medicus Pharma reported a net loss of $47.3 million, compared with a loss of $11.2 million a year earlier. Diluted earnings per share came in at -$2.74.

Medicus Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-47.28M$-11.16M$-5.31M
EPS (diluted)$-2.74$-1.16$-1.53

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$4.50+296.48%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-11.64 vs $-8.50
Surprise
-36.94%

MDCX news

All MDCX news

Medicus Pharma peers

Health Care sector
MDCX peer companies
CompanyPrice% ChgMarket capCompare
KPRXKiora Pharmaceuticals Inc.0.7202-12.28%$3.19Mvs MDCX
NRSNNeuroSense Therapeutics Ltd.1.28+1.59%$3.19Mvs MDCX
AZTRAzitra Inc0.5168-2.75%$3.13Mvs MDCX
GELSGelteq Limited0.2701-3.74%$3.11Mvs MDCX
SKYESkye Bioscience Inc.0.70-11.03%$3.10Mvs MDCX
APREAprea Therapeutics Inc.0.229-53.56%$3.25Mvs MDCX
XBIOXenetic Biosciences Inc.1.40-9.09%$3.28Mvs MDCX
JAGXJaguar Health Inc.0.227-30.58%$3.03Mvs MDCX

Indexes, lists and sector

Medicus Pharma stock FAQ

What is Medicus Pharma's stock price today?

MDCX last traded at $1.14 as of Nov 20, 4:00 PM EST, down 2.16% on the day. Prices are delayed at least 15 minutes.

Does Medicus Pharma pay a dividend?

No. Medicus Pharma does not currently pay a regular cash dividend.

Who is Medicus Pharma's CEO?

Dr. Raza Bokhari M.B.A., M.D. is the chief executive officer of Medicus Pharma Ltd., which has about 16 employees.

Has MDCX ever split its stock?

Yes. The most recent MDCX stock split was a 1-for-50 split on Oct 12, 2026.

What is the MDCX 52-week high?

The 52-week high for MDCX is $114.00 and the 52-week low is $1.06. The stock is currently 99.0% below its high.

Compare MDCX